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The nonstructural protein NS1A from inﬂuenza virus is a
multifunctional virulence factor and a potent inhibitor of host
immunity. It has two functional domains: an N-terminal
73-amino-acid RNA-binding domain and a C-terminal
effector domain. Here, the crystallographic structure of the
NS1A effector domain of inﬂuenza A/Udorn/72 virus is
presented. Structure comparison with the NS1 effector
domain from mouse-adapted inﬂuenza A/Puerto Rico/8/34
(PR8) virus strain reveals a similar monomer conformation
but a different dimer interface. Further analysis and evalua-
tion shows that the dimer interface observed in the structure
of the PR8 NS1 effector domain is likely to be a crystallo-
graphic packing effect. A hypothetical model of the intact NS1
dimer is presented.
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1. Introduction
Inﬂuenza viruses are the causative agents of an infectious and
debilitating disease commonly referred to as the ﬂu. The virus
has a complex replicative cycle (Lamb & Krug, 2001) and
undergoes rapid evolutionary divergence (Webby & Webster,
2001). In its most aggressive form, the virus was responsible
for one of the most devastating pandemics in human history:
the notorious Spanish ﬂu caused 20–40 million deaths world-
wide in the early twentieth century. In 1997, a deadly inﬂuenza
A virus strain H5N1 was transmitted from birds to humans in
Hong Kong, resulting in six deaths among 18 infected persons.
This H5N1 subtype also caused disease outbreaks in poultry in
Asia, Europe and Africa during late 2003 and early 2004. The
H5N1-subtype inﬂuenza Aviruses have the potential to cause
the next pandemic if they acquire an efﬁcient ability to spread
easily among human beings. There is currently great interest in
deﬁning inﬂuenza targets for the design of efﬁcacious antiviral
agents that can complement ongoing efforts towards vaccine
development.
The genome of inﬂuenza A virus is composed of eight
segments of single-stranded RNA. Segment 8 encodes a
26 kDa protein called NS1. NS1 is designated as a non-
structural protein because it is synthesized in infected cells but
is not incorporated into virions; this makes it less subject to
selective pressure than virus-coat proteins such as the
hemagglutinin and neuraminidase proteins that give rise to the
inﬂuenza serotype names. It has been proven that the NS1A
protein can be targeted for the development of new antiviral
drugs (Min & Krug, 2006; Twu et al., 2006).
The NS1 protein is a multifunctional protein that partici-
pates in both protein–protein and protein–RNA interactions(Krug et al., 2003). NS1 has two functional domains: the
N-terminal 73-amino-acid RNA-binding domain (RBD) and
the C-terminal effector domain. The RBD binds nonspeciﬁ-
cally to double-stranded RNA (dsRNA) and protects the virus
against the antiviral state induced by interferon  / . It was
subsequently discovered that this protection is achieved by
blocking the activation of the 20-50-oligo(A) synthetase/RNase
L pathway (Min & Krug, 2006). The RBD also overlaps the
retinoic acid-inducible gene I (RIG-I) binding domain
(Mibayashi et al., 2007). The RIG-I protein functions as an
intracellular viral sensor which can be activated by inﬂuenza
virus ssRNA. The binding of RIG-I to RBD of NS1 inhibits
the viral detection ability of the cell.
The C-terminal effector domain has been found to interact
with at least four different proteins: elongation initiation
factor 4GI (eIF4GI), protein kinase R (PKR), poly(A)-
binding protein II (PAB II) and the cleavage and 30 kDa
subunit of the polyadenylation speciﬁcity factor (CPSF30).
When the effector domain binds to CPSF30, it inhibits the
maturation and export of host cellular antiviral mRNAs
(Noah et al., 2003). The second and third zinc ﬁngers (F2F3) of
CPSF30 have been shown to mediate the binding of NS1A
(Twu et al., 2006). The validity of the NS1 effector domain as a
potential drug target has been attested to by a mutational
analysis. NS1 mutations spanning the CPSF30-binding site
(residues 184–188) reduce CPSF30 binding. Recombinant
virus expressing these mutations induced a high level of
host-cell interferon   (INF- ), while viral replication was
attenuated 1000-fold (Noah et al., 2003). In addition, an
engineered MDCK cell line which constitutively expresses
epitope-tagged F2F3 in the nucleus effectively blocked the
binding of endogenous CPSF30 to NS1A and thereby selec-
tively inhibited inﬂuenza virus A replication (Twu et al., 2006).
Taken together, these experiments suggest that the CPSF30
binding site can be targeted for the development of new
antiviral drugs.
Although the structure of full-length NS1A is not available,
the structures of the two functional domains have been solved
independently. NMR (Chien et al., 1997) and X-ray structures
(Liu et al., 1997) of the 73-residue N-terminal domain of NS1A
have been reported. They show that the protein is active as a
dimer. The structural analysis revealed a unique six-helix
structure for the dimer, which differs from that of the
predominant class of dsRNA-binding proteins. The dimeric
protein binds dsRNA as part of its function in the viral cycle.
The X-ray structure of the NS1 effector domain (residues
79–205) of the mouse-adapted inﬂuenza A/Puerto Rico/8/34
(PR8) virus strain has been solved recently (Bornholdt &
Prasad, 2006). Like the N-terminal domain, the effector
domain forms a dimer in solution. Each monomer consists of
seven  -strands and three  -helices. The structure is believed
to be a novel fold, which can be described as an  -helix
 -crescent fold, as the  -strands form a crescent-like shape
about the central  -helix. The NS1A from the PR8 virus strain
does not bind CPSF30. It is thought that this arises from two
mutations (F103S and M106I) in the F2F3-recognition site. As
the CPSF30-binding site is crucial for virus replication and a
proven target for new antiviral drug development, it is
important to analyze the structure of an NS1 effector domain
that does interact with CPSF30 (Twu et al., 2006). Recently, the
X-ray structure of a complex between the inﬂuenza A/Udorn/
72 NS1A effector domain and the F2F3 domain of CPSF30 has
been published (Das et al., 2008). The key observation is that
aromatic side chains from the F3 zinc ﬁnger (Phe97, Phe98 and
Phe102) bind into a hydrophobic pocket in the effector
domain. Here, we report the crystal structure of the 126-
residue C-terminal effector domain (residues 79–205) of
NS1A from the inﬂuenza A/Udorn/72 virus strain at 2.3 A ˚
resolution and compare it with the structure of the PR8 virus
strain NS1 effector domain, which has 89% sequence identity.
2. Materials and methods
2.1. Purification and expression
The gene expressing the inﬂuenza A/Udorn/72 NS1A
effector domain, a polypeptide consisting of 126 amino acids
(residues 79–205), was cloned by ﬁrst amplifying the DNA
with primers GACGACGACAAGATGACCATGGCCTCC-
ACACC and GAGGAGAAGCCCGGTTTAGCTTCCCCA-
AGCGAATC. The product was cloned into pET-46 Ek/LIC
(Novagen). The integrity of the cloned DNAwas conﬁrmed by
DNA sequencing. Escherichia coli strain Rosetta 2 (DE3)
(Novagen) containing the plasmid was grown overnight in
broth medium [1%(w/v) tryptone, 0.5%(w/v) yeast extract,
0.5%(w/v) NaCl] containing ampicillin (100 mgm l
 1) and
chloramphenicol (34 mgm l
 1) at 310 K. The cells were then
diluted 1:100 in 2 l medium and grown to a cell density of
approximately 4   10
8 per millilitre. IPTG was added to 1 mM
and the cells were grown overnight at 298 K. The protein,
residues 79–205 of the inﬂuenza A/Udorn/72 NS1A with a
14-residue His tag (MAHHHHHHVDDDDK) attached at
the N-terminal end, was puriﬁed essentially according to a
procedure developed by Novagen. Brieﬂy, cells were collected
by centrifugation, resuspended in 25 ml column buffer (CB;
50 mM HEPES pH 8.0, 300 mM NaCl, 20 mM imidazole) and
disrupted in a French pressure cell. Cellular debris was
pelleted by centrifugation at 5000g for 60 min at 277 K. The
supernatant was applied onto a column containing Ni–NTA
His-binding beads (2 ml bed volume, equilibrated with CB),
washed with 100 ml CB and then eluted with 10 ml elution
buffer (EB; 50 mM HEPES pH 8.0, 300 mM NaCl, 250 mM
imidazole). The protein was concentrated to 1–2 ml using an
Amicon bioseparator ﬁtted with a 45 mm YM-3 membrane
and applying 414–483 kPa N2 at 277 K. The concentrated
sample then underwent size-exclusion chromatography with a
50 mM HEPES pH 8.0, 100 mM NaCl buffer.
2.2. Crystallization
One crystal form (I) of the inﬂuenza A/Udorn/72 NS1A
effector domain was grown at room temperature using the
batch method by mixing 5 ml1 0 m g m l
 1 NS1A effector
domain in 50 mM HEPES pH 8.0, 0.1 M NaCl with 5 ml
20%(w/v) PEG 400, 0.1 M sodium acetate pH 5.5, 0.1 M
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in the high-throughput crystallization screening laboratory at
the Hauptman–Woodward Medical Research Institute (Luft et
al., 2003). A second crystal form (II) was grown at 277 Kusing
the sitting-drop method. 5 ml protein solution (10 mg ml
 1 in
50 mM HEPES pH 8.0, 0.1 M NaCl) was mixed with 5 ml
reservoir solution and equilibrated against a reservoir
containing 800 ml 12%(w/v) PEG 3350 and 4%(v/v) Tacsimate
pH 6.0. This condition was found using the Hampton Research
PEG/Ion HT Screen kit.
2.3. Data collection and processing
Crystal form I of the inﬂuenza A/Udorn/72 NS1A effector
domain was cryoprotected by dipping it into an artiﬁcial
mother liquor containing 30% PEG 400. Crystal form II was
similarly cryoprotected with an artiﬁcial mother liquor con-
taining 20% PEG 3350. Crystals mounted in a cryoloop
(Hampton Research) were ﬂash-frozen by dipping them into
liquid nitrogen and were placed in the cold stream on the
goniostat. Diffraction data were collected at 100 K on a MAR
345 image-plate detector (MAR Research) with X-rays
generated by a Rigaku Micromax007 rotating-anode
generator (Rigaku, The Woodlands, Texas, USA) operated at
40 mV and 30 mA. Diffraction data were collected using a
crystal-to-detector distance of 200 mm. Diffraction data were
integrated and scaled using HKL-2000 (Otwinowski & Minor,
1997). Crystal form I (grown at pH 5.5 and room temperature)
was determined to belong to space group P212121, with unit-
cell parameters a = 47.9, b = 61.5, c = 132.1 A ˚ . The second
crystal form, grown at pH 6.0 and 277 K, belonged to space
group C2221, with unit-cell parameters a = 62.8, b = 74.0,
c = 121.9 A ˚ .
2.4. Structure determination and refinement
Molecular-replacement solutions for both crystal forms
were obtained using the inﬂuenza A/Puerto Rico/8/34 NS1
protein as a model (PDB code 2gx9; Bornholdt & Prasad,
2006); the searches were conducted using the program
MOLREP (Vagin & Teplyakov, 1997). Rigid-body reﬁnement
of the molecular-replacement solutions was performed using
CNS (Bru ¨nger et al., 1998). Subsequent reﬁnement of atomic
positions and isotropic B factors was performed using CNS
and REFMAC (Collaborative Computational Project, Num-
ber 4, 1994; Murshudov et al., 1997). Molecular visualization
and rebuilding were performed using Coot (Emsley &
Cowtan, 2004). Water and sulfate molecules were identiﬁed
using Coot based on an Fo   Fc difference map. 5% of the
diffraction data were set aside throughout reﬁnement for
cross-validation (Bru ¨nger, 1993). PROCHECK was used to
produce the Ramachandran plots (Laskowski et al., 1993).
Model pictures were produced using PyMOL (DeLano
Scientiﬁc, San Carlos, California, USA).
3. Results and discussion
3.1. X-ray structure determination
Recombinant His-tagged inﬂuenza A/Udorn/72 NS1A
effector domain (residues 79–205) was expressed in good yield
from E. coli ( 10 mg per litre of cell culture). A screen of
crystallization conditions produced two useful forms. The best
crystals of the NS1A effector domain grew at room
temperature at pH 5.5 and were found to belong to space
group P212121, with unit-cell parameters a = 47.9, b = 61.5,
c = 132.1 A ˚ . In this crystal form there are two molecules per
asymmetric unit, giving a VM value of 3.04 A ˚ 3 Da
 1
(Matthews, 1968). A second useful form grew at 277 K at pH
6.0. These crystals belonged to space group C2221, with unit-
cell parameters a = 62.8, b = 74.0, c = 121.9 A ˚ . These crystals
also contained two molecules in the asymmetric unit, giving a
VM value of 2.21 A ˚ 3 Da
 1. X-ray data and reﬁnement statistics
for the two structures are shown in Table 1. A section of the
ﬁnal 2Fo   Fc electron-density map used for model
construction from the pH 5.5 crystal is shown in Fig. 1.
Following reﬁnement, a Ramachandran plot of the pH 5.5
crystal structure (space group P212121) shows 87.1% of resi-
dues to be in the most favorable region and 12.9% to be in
additionally allowed space. The reﬁned structure includes two
sulfate ions and 136 solvent molecules. The pH 6.0 crystal
structure (space group C2221) gives a Ramachandran plot with
87.3% of residues in the most favorable region and 12.7% in
additionally allowed space. This reﬁned structure includes 20
solvent molecules.
3.2. Structure of the influenza A/Udorn/72 NS1A effector
domain
The structure of the inﬂuenza A/Udorn/72 NS1A effector
domain shows an  -helix  -crescent fold that is generally
similar to that of the PR8 NS1 effector domain (Bornholdt &
Prasad, 2006) and that of the recently solved NS1A effector
research papers
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Table 1
Data-collection and model-reﬁnement statistics.
Values in parentheses are for the highest resolution shell.
Data collection
Wavelength (A ˚ ) 1.5418 1.5418
Space group P212121 C2221
Unit-cell parameters (A ˚ ) a = 47.92, b = 61.46,
c = 132.13
a = 62.82, b = 74.03,
c = 121.88
Resolution (A ˚ ) 30–2.3 (2.38–2.30) 30–2.8 (2.90–2.80)
Rmerge (%)† 6.8 (26.3) 6.1 (14.6)
hI/ (I)i 11.8 (2.7) 16.0 (4.8)
Completeness 98.1 (83.5) 96.8 (79.0)
Redundancy 6.4 (4.1) 7.4 (3.1)
Reﬁnement
No. of reﬂections 17766 7261
No. of protein atoms 1909 1923
No. of solvent atoms 136 20
No. of sulfate atoms 10 0
Rworking 0.197 (0.234) 0.197 (0.235)
Rfree 0.232 (0.287) 0.284 (0.316)
Average B factor
for protein atoms (A ˚ 2)
35.4 38.8
R.m.s deviations from ideality
Bond lengths (A ˚ ) 0.011 0.014
Bond angles ( ) 1.236 1.482
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ.domain from an avian inﬂuenza virus (Hale
et al., 2008). A ribbon drawing of the inﬂu-
enza A/Udorn/72 NS1A effector domain is
shown in Fig. 2. There are seven  -strands
and three  -helices in each monomer
subunit. Six of the  -strands surround a long
central  -helix and make an extensive
network of hydrophobic interactions with it.
It is these interactions around one side of
the helix that give rise to the rough crescent
shape.
As shown in Fig. 2, the ﬁrst  -strand (a)
lies on the convex side of the crescent and is
connected by a short helix A to strand b.
Five  -strands (b, c, d, e and f) then
sequentially connect to each other to form
an antiparallel twisted  -sheet that
surrounds the central helix B. Helix B is the
longest  -helix of the structure; it connects
strand f to strand g, which lies adjacent and
antiparallel to strand d. Strand g is followed
by the last helix C, which lies at the the sharp
end of the crescent. One sulfate ion is
observed in each monomer and forms
hydrogen bonds to the side chains of Gln199
and Arg193.
The inﬂuenza A/Udorn/72 NS1A effector
domain and the PR8 NS1 effector domain
share 89% sequence identity and conse-
quently the overall folding of the two
structures is quite similar. Superposition of
the two structures, shown in Fig. 3, gives an
r.m.s. distance between 81 equivalent C
 
atoms of 0.29 A ˚ . The most obvious differ-
ences between the two structures lie at the
N-terminus and in two loop regions. Ser87 is
near the N-terminus and marks that region;
residues 135–143 (labeled Phe138) are
shifted up to 5 A ˚ towards strands a and d.
The second loop region, residues 163–168
(labeled Pro167), is shifted towards strand b
by  3A ˚ in the inﬂuenza A/Udorn/72 NS1A
structure. Trp187, which is crucial to
effector-domain function, is shown for
reference.
3.3. Effector-domain dimerization
The NS1 effector domain behaves as a
dimer in solution based on its chromato-
graphic properties (Nemeroff et al., 1995).
Not surprisingly, the asymmetric unit in both
of our crystal forms of the inﬂuenza A/
Udorn/72 NS1A is a dimer. In both of our
crystal structures, the main stabilizing
interaction for noncrystallographic dimer
formation appears to be the pseudo-
research papers
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Figure 2
Ribbon drawing of the effector domain of inﬂuenza A/Udorn/72 NS1A.  -Helices and
 -strands arelabeled and the side chain of Trp187 is shown in order tomark the binding site for
CPSF30.
Figure 3
Superposition of the inﬂuenza A/Udorn/72 NS1A effector domain and the PR8 NS1 effector
domain (PDB code 2gx9; Bornholdt & Prasad, 2006). The C
  trace of the inﬂuenza A/Udorn/
72 NS1A effector domain is shown in blue bonds and that of the PR8 NS1 effector domain is
shown in red bonds. The side chain of Trp187, indicating the area of the effector domain-
binding pocket, is also shown.
Figure 1
Electron density for the inﬂuenza A/Udorn/72 NS1A effector domain. This is a section of a
2Fo   Fc map contoured at 1  to show the interface of the effector-domain dimer.symmetrical insertion of the Trp187 indole ring into the
hydrophobic F2F3-binding pocket of its dimer partner; the
dimer interface is shown in Fig. 4. Fig. 4(a) shows a space-
ﬁlling model of a monomer subunit, with the Trp187 side chain
of the other subunit ﬁtting into it; Fig. 4(b) shows further
details of the interactions of the buried Trp187 side chain with
the hydrophobic binding pocket. The pocket is formed by
main-chain residues Gly183–Asn188 together with the side
chains of residues Lys108, Lys110, Ile117, Gln121 and Val180.
The hydrophobic pocket is located at the base of the central
long helix, with the side chain of Trp187 pointing outwards
from the periphery. The recently obtained X-ray structure of
the inﬂuenza A/Udorn/72 NS1A effector domain bound to
F2F3 (Das et al., 2008) shows that this hydrophobic pocket is
indeed the CPSF30-binding pocket. This is consistent with the
observation that residues Gly184–Asn188 are crucial for
binding to the CPSF30 subunit and are highly conserved
among human inﬂuenza A viruses, including the inﬂuenza A/
Hongkong/493/1997 virus and the inﬂuenza A/Vietnam/1203/
2004 virus (Twu et al., 2007).
The X-ray structure of an avian virus NS1 effector domain
(Hale et al., 2008) also exhibited a noncrystallographic dimer
very similar to that seen in our two inﬂuenza A/Udorn/72
NS1A structures. The authors also realised the importance of
the interaction of Trp187 with the CPSF30-binding site. They
mutated three residues near the dimeric interface to alanines,
M106A, Q121A and W187A, but only the
tryptophan alteration caused the protein to
act as a monomer in solution.
The PR8 NS1 effector domain also forms
a noncrystallographic dimer and has the
same kind of interface as described here
(Bornholdt & Prasad, 2006). The authors of
this study focused their attention not on the
Trp187 contact but on the formation of a
segment of antiparallel  -sheet between the
N-terminal strands of the neighboring
molecules. This  -sheet pairing is not seen in
either of our structures nor in the avian virus
structure and appears to result from
adventitious crystal-packing forces that are
unique to the PR8 NS1 crystal. The pseudo-
dimeric interaction of Trp187 with the F2F3-
binding site is common to all four structures
and is clearly the main interaction driving
effector-domain dimerization, as conﬁrmed
by the recent mutagenic studies.
Fig. 5 shows the relative orientations of
the noncrystallographic dimers from our
two crystal forms of the inﬂuenza A/Udorn/
72 NS1A effector domain. One monomer
subunit from each structure superimposes in
a least-squares sense with an r.m.s. deviation
of 0.28 A ˚ for C
  atoms. In each case its
dimeric partner makes interactions similar
to those described above, burying the
Trp187 side chain in the neighboring binding
site (the side chains are shown and labeled).
However, subtle differences at the interface
generate rather large differences for remote
regions of the molecule. To superpose the
second monomer subunit from the two
systems requires a rotation of 44 .T h e
central B helices of the monomers are
shown as cartoons in Fig. 5 in order to
facilitate the comparison. The orientation of
the PR8 NS1 effector-domain dimer is
similar but not identical to that of the space
group C2221 inﬂuenza A/Udorn/72 NS1A
crystal (red in Fig. 5). Again, the dimer
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Figure 4
The dimer interface for the inﬂuenza A/Udorn/72 NS1A effector domain. (a) A space-ﬁlling
model of monomer subunit A reveals a distinct largely hydrophobic pocket that has evolved to
bind aromatic residues from the F2F3 domain of CPSF30. Here, Trp187 from effector domain
monomer subunit B (shown in blue) binds in that pocket. (b) A detailed view of the
interactions of Trp187 with monomer subunit A binding-cleft residues (shown in green).interface is basically the same in all the crystal structures;
however, subtle differences at the interface still allow larger
differences in the crystal packing of the entire dimer.
In discussing the F2F3-binding site of the NS1 effector
domain, it is interesting to note that the pocket residues
Lys108, Lys110, Ile117, Gln121, Val180 and Gly183–Trp187
are conserved among almost all inﬂuenza Aviruses, including
those having an intrinsic defect in binding CPSF30. It appears
that proteins such as PR8 NS1 that are defective in CPSF30
binding lack the consensus amino acids Phe103 and Met106.
The recent structure of the inﬂuenza A/Udorn/72 NS1A
effector domain with the F2F3 fragment of CPSF30 bound
reveals that Phe103 and Met106 are not part of the CPSF30-
binding pocket, but are involved in intermolecular inter-
actions that stabilize the complex at a site remote from the
hydrophobic pocket. Phe102 and Met106 are not involved in
the dimerization of the inﬂuenza A/Udorn/72 NS1A effector
domain either, as shown in Fig. 4(b).
3.4. Model of intact NS1
As described in x1, NS1 is a functional dimer with two major
domains (Nemeroff et al., 1995). We recently solved the
structure of the NS1A N-terminal domain, residues 1–79
(unpublished data), but found that it was the same as that
described previously for residues 1–73 (Liu et al., 1997). In our
structure we note that residues beyond 73 are not observed,
presumably because they are disordered. In the C-terminal
effector domain reported here, residues 79–83 are not
observed in either crystalline form, again because they are
likely to be disordered. This suggests that there is a ﬂexible
linker region of about ten amino acids (residues 74–83)
between the two domains.
The NS1 dimer is maintained by dimerization of the
N-terminal domain (Wang et al., 1999) and it may be that the
effector domains of NS1 also participate in NS1 dimerization
(Wang et al., 2002). It is likely that in the NS1 dimer the
effector domains dimerize in a manner similar to that which
we and others have observed crystal-
lographically. To help understand the action
of the NS1 effector-domain dimers, in which
the biologically important CPSF30-binding
sites are buried, we constructed a hypothe-
tical model of the intact NS1 dimer. This
model is illustrated in Fig. 6. To build the
model, we aligned the twofold axes of the N-
terminal and C-terminal dimers and rotated
them so as to bring the C-terminal residues
of the N-terminal domain near the N-term-
inal residues of the C-terminal domain. We
found that this was very straightforward and
allowed the domains to be linked plausibly
by a ten-residue linker. We minimized the
energy of the model using CNS (Bru ¨nger et
al., 1998). In Fig. 6, the N-terminal domains
are shades of blue for chain 1 and cyan for
chain 2. The effector domains are shades of
red for chain 1 and orange for chain 2. The ten-residue linkers
are colored yellow. The Trp187 side chains are shown as van
der Waals structures and chain 1 is labeled; the indole ring
binds deep in the pocket of chain 2. We have also added a
plausible binding site for dsRNA to the NS1 model. RNA is
thought to bind in the prominent channel between symme-
trical helices 2 of the N-terminal dimer. The RNA binding is
stabilized by a number of ionic interactions (Wang et al., 1999).
This notion has been given strong support from site-directed
mutations which show, among other things, that Arg38 is
essential to dsRNA binding. This key side chain is shown as
stick bonds pointing to the dsRNA; Arg38 on chain 1 is
labeled and also serves to identify helix 2 which forms the
binding channel.
In the NS1 dimer, it is likely that the effector domains
dimerize such that for each subunit the Trp187 side chain is
buried in the hydrophobic pocket of its dimer partner. The
binding of CPSF30 is likely to require a large quaternary
structural change to the effector-domain dimer. Initially, the
CPSF30-binding pocket is probably blocked by the Trp187
side chain of its dimeric partner, as seen in Fig. 6. In order to
bind CPSF30, the Trp187 side chain must be displaced and the
effector domains rotate to accommodate CPSF30 phenyl-
alanines 97, 98 and 103. It is clear from our model that the long
unstructured linkers would allow the effector domains to
rotate freely into the solvent from the stable N-terminal
domain platform. Presumably, there is an equilibrium between
the dimerized state that we observe in the crystal structure and
a more open conformation. If that open form interacts with
the F2F3 domain of CPSF30, those interactions are presum-
ably much stronger than the internal dimer. The effector
domains of NS1 proteins that do not bind CPSF30, such as the
PR8 NS1, also form dimers with Trp187 pointing into hydro-
phobic pocket of an adjacent monomer and presumably also
have some open conformation. However, without Phe at
position 103 and Met at position 106 to help stabilize the F2F3
interactions, the internal effector-domain dimer may be more
stable. This would explain why all inﬂuenza viruses have this
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Figure 5
Superposition of the inﬂuenza A/Udorn/72 NS1A effector domain (pH 5.5 structure; blue) and
the PR8 NS1 effector domain (red).conserved hydrophobic pocket, but only viruses with Phe at
position 103 and Met at position 106 are able to break their
internal dimer and bind CPSF30 (Twu et al., 2007).
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Figure 6
Hypothetical model of intact NS1. One chain has the N-terminal domain
colored blue and the effector domain colored red; the second chain is
colored cyan and orange, respectively. A ten-residue linker (yellow) joins
the domains which have been observed crystallographically.